Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30278664 | 1.00 | MEN1 (0.48) | MEN1KMT2ATDP1NPC1RAB9A | |
| SCHEMBL13023542 | 0.90 | HDAC3 (0.49) | MEN1KMT2ATDP1NPC1RAB9A | |
| SCHEMBL13065996 | 0.90 | HDAC3 (0.49) | MEN1KMT2ATDP1NPC1RAB9A | |
| SCHEMBL6403303 | 0.87 | HDAC3 (0.48) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL4474989 | 0.86 | EGFR (0.49) | MEN1KMT2ATDP1NPC1RAB9A | |
| SCHEMBL4500941 | 0.85 | PDK1 (0.59) | MEN1KMT2ANPC1RAB9ASIRT2 | |
| SCHEMBL30849775 | 0.85 | PDK1 (0.59) | MEN1KMT2ANPC1RAB9ASIRT2 | |
| SCHEMBL16953907 | 0.85 | HDAC3 (0.47) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL15584537 | 0.85 | HDAC4 (0.44) | MEN1KMT2ATDP1NPC1RAB9A | |
| SCHEMBL29029431 | 0.84 | HDAC3 (0.56) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023005263-A1 | RESIN COMPOSITION, RESIN FILM, AND DISPLAY DEVICE | 吉林奥来德光电材料股份有限公司 | 2023-02-02 | — | — | WO | disclosed |
| US-11535643-B2 | Macrolides with modified desosamine sugars and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-27 | — | — | US | disclosed |
| US-11535643-B2 | Macrolides with modified desosamine sugars and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220354959-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. (US) | 2022-11-10 | — | — | US | disclosed |
| EP-3544970-B1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-3901162-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | AbbVie Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200377542-A1 | MACROLIDES WITH MODIFIED DESOSAMINE SUGARS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200338208-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2008118379-A2 | AMINO-5-[4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF β-SECRETASE | WYETH (US) | 2008-10-02 | — | — | WO | disclosed |
| US-7417047-B2 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation | WYETH (US) | 2008-08-26 | — | — | US | disclosed |
| WO-2008061236-A2 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
| US-7169797-B2 | Protein-tyrosine phosphatase inhibitors and uses thereof | ABBOTT LABORATORIES (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| EP-1737463-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005060970-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| US-20040214870-A1 | Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; 5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid | ABBVIE INC. | 2004-10-28 | — | — | US | disclosed |
| US-20040167188-A1 | Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; | ABBOTT LABORATORIES | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | MEN1 1088/4885KMT2A 180/4885TDP1 1000/4885 |
| US-20200338208-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | MEN1 3523/4885KMT2A 4137/4885TDP1 3874/4885 |
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | IRAK1, IRAK4, IRAK2 | MEN1 1933/4885KMT2A 1447/4885TDP1 425/4885 |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | IRAK1, IRAK4, IRAK2 | MEN1 1933/4885KMT2A 1447/4885TDP1 425/4885 |
| US-11535643-B2 | Macrolides with modified desosamine sugars and uses thereof | FUT6, MGAM, B3GNT2 | MEN1 702/4885KMT2A 1688/4885TDP1 4647/4885 |
| US-20200377542-A1 | MACROLIDES WITH MODIFIED DESOSAMINE SUGARS AND USES THEREOF | FUT6, MGAM, B3GNT2 | MEN1 702/4885KMT2A 1688/4885TDP1 4647/4885 |
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | BACE1, BACE2, APP | MEN1 4193/4885KMT2A 3216/4885TDP1 839/4885 |
| US-20220354959-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | MEN1 3523/4885KMT2A 4137/4885TDP1 3874/4885 |
| US-20040167188-A1 | Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; | G6PC1, PPP1R1B, PPP1R7 | MEN1 2107/4885KMT2A 2609/4885TDP1 1078/4885 |
| US-20040214870-A1 | Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; 5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid | G6PC1, PPP1R7, PPP1R1B | MEN1 3309/4885KMT2A 2348/4885TDP1 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.